Population pharmacokinetics of exenatide.

Cirincione B, Mager DE

British journal of clinical pharmacology16 Nov 2016Cited by 32 (Europe PMC)

PMID27650681PMCIDPMC5306477DOI10.1111/bcp.13135PepBankPUB-27650681

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. 5 results from people.

01HumanOther designPharmacokinetics
In population pharmacokinetic modelling of data from eight clinical trials, exenatide had two-compartment disposition and sequential zero-order then saturable nonlinear subcutaneous absorption.
In plain wordsIn a model built from data of eight clinical trials, exenatide followed a two-compartment model.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDisposition model
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
The pharmacokinetics of IR exenatide was described by a two-compartment model, and the absorption of subcutaneous exenatide was described with a sequential zero-order rate constant followed by a saturable nonlinear absorption process.
2 context sentences(design, population, supporting numbers)
Summary · context
Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis.
Summary · context
All modelling and simulations were conducted using the nonlinear mixed-effect modelling program NONMEM.
Report a problemFND-2765068101
02HumanOther designPharmacokinetics
In population pharmacokinetic modelling of data from eight clinical trials, exenatide linear clearance was estimated at 5.06 l per hour for a subject with normal renal function.
In plain wordsIn a model built from data of eight clinical trials, exenatide clearance was estimated at 5.06 l per hour with normal kidney function.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableLinear clearance
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Measurements
Linear clearance
5.06 l hr-1
normal renal function
Source sentences
Summary
For a subject with normal renal function, the linear clearance was estimated to be 5.06 l hr^-1 .
2 context sentences(design, population, supporting numbers)
Summary · context
Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis.
Summary · context
All modelling and simulations were conducted using the nonlinear mixed-effect modelling program NONMEM.
Report a problemFND-2765068103
03HumanOther designPharmacokinetics
In population pharmacokinetic modelling of data from eight clinical trials, exenatide nonlinear elimination had a Michaelis-Menten constant of 567 pg/ml.
In plain wordsIn a model built from data of eight clinical trials, exenatide nonlinear elimination had a Michaelis-Menten constant of 567 pg/ml.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableMichaelis-Menten constant
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Measurements
Michaelis-Menten constant (Km)
567 pg ml-1
exenatide nonlinear elimination
Source sentences
Summary
The nonlinear elimination was quantified with a Michaelis-Menten constant (K_m ) of 567 pg ml^-1 and a maximum rate of metabolism (V_max ) of 1.6 μg h^-1 .
2 context sentences(design, population, supporting numbers)
Summary · context
Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis.
Summary · context
All modelling and simulations were conducted using the nonlinear mixed-effect modelling program NONMEM.
Report a problemFND-2765068104
04HumanOther designPharmacokinetics
In population pharmacokinetic modelling of data from eight clinical trials, exenatide maximum rate of metabolism was 1.6 μg per hour.
In plain wordsIn a model built from data of eight clinical trials, exenatide maximum rate of metabolism was 1.6 μg per hour.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableMaximum metabolic rate
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Measurements
Maximum rate of metabolism (Vmax)
1.6 μg h-1
exenatide nonlinear elimination
Source sentences
Summary
The nonlinear elimination was quantified with a Michaelis-Menten constant (K_m ) of 567 pg ml^-1 and a maximum rate of metabolism (V_max ) of 1.6 μg h^-1 .
2 context sentences(design, population, supporting numbers)
Summary · context
Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis.
Summary · context
All modelling and simulations were conducted using the nonlinear mixed-effect modelling program NONMEM.
Report a problemFND-2765068105
05HumanOther designPharmacokinetics
In population pharmacokinetic modelling of data from eight clinical trials, 37% of the subcutaneous exenatide dose was absorbed by the zero-order process and 63% by the nonlinear pathway.
In plain wordsIn a model built from data of eight clinical trials, 37% of exenatide was absorbed through a zero-order process and 63% through a nonlinear pathway.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableSubcutaneous absorption pathways
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · subcutaneousAs given in this study (Human).
Measurements
Absorption via zero-order process
37%
subcutaneous exenatide dose
Absorption via nonlinear pathway
63%
subcutaneous exenatide dose
Source sentences
Summary
For subcutaneous administration, 37% of the subcutaneous dose is absorbed via the zero-order process, and the remaining 63% via the nonlinear pathway.
2 context sentences(design, population, supporting numbers)
Summary · context
Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis.
Summary · context
All modelling and simulations were conducted using the nonlinear mixed-effect modelling program NONMEM.
Report a problemFND-2765068106

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

06HumanNot a test of Exenatide (exendin-4) aloneOther designPharmacokinetics
In population pharmacokinetic modelling of data from eight clinical trials, exenatide had parallel linear and nonlinear elimination, with renal function significantly related to linear elimination.
In plain wordsIn a model built from data of eight clinical trials, kidney function related to the linear route of exenatide elimination.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableRenal function and linear elimination
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Drug elimination was characterized by two parallel routes (linear and nonlinear), with significant relationships between renal function and the linear elimination route, and between body weight and volume of distribution.
2 context sentences(design, population, supporting numbers)
Summary · context
Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis.
Summary · context
All modelling and simulations were conducted using the nonlinear mixed-effect modelling program NONMEM.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2765068102
07HumanNot a test of Exenatide (exendin-4) aloneOther designPharmacokinetics
In population modelling of exenatide, body weight was significantly related to volume of distribution.
In plain wordsIn computer models, body weight related to exenatide distribution volume.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableBody weight and distribution volume
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Drug elimination was characterized by two parallel routes (linear and nonlinear), with significant relationships between renal function and the linear elimination route, and between body weight and volume of distribution.
2 context sentences(design, population, supporting numbers)
Summary · context
Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis.
Summary · context
All modelling and simulations were conducted using the nonlinear mixed-effect modelling program NONMEM.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2765068107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.